Clinical Trial Update: ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating ATLCAR.CD30.CCR4 for CD30+ Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• ATLCAR.CD30.CCR4 (ATLCAR.CD30.CCR4)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Hodgkin Lymphoma, Relapse | Phase 1, Phase 2 | Status: RECRUITING